<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737967</url>
  </required_header>
  <id_info>
    <org_study_id>CIPN101</org_study_id>
    <nct_id>NCT04737967</nct_id>
  </id_info>
  <brief_title>The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy</brief_title>
  <official_title>The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mendel AI</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mendel AI</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blinded two-arm randomized case-only interventional trial. A total of 60&#xD;
      patients who are to receive Paclitaxel to be included and allocated in two groups. The&#xD;
      protocol is to be reviewed by the Research Ethics Committee of Faculty of Medicine Cairo&#xD;
      University.&#xD;
&#xD;
      All procedure will be done in Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine.&#xD;
&#xD;
      The first arm (Venlafaxine group) will receive Venlafaxine extended release (37.5 mg) tablets&#xD;
      (Zimmerman et al., 2016).&#xD;
&#xD;
      The second arm (Memantine group) will receive memantine 10 mg once daily (Morel et al., 2016)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average daily pain intensity</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in average daily pain intensity as measured by the Brief Pain Inventory- Short Form (BPI-SF). Absolute change in the average daily pain intensity as measured by the Brief Pain Inventory- Short Form (BPI-SF) from baseline to the end of 6 weeks measured by item # 5 of Brief Pain Inventory Score (BPI-SF). The BPI assesses pain at its &quot;worst,&quot; &quot;least,&quot; &quot;average,&quot; and &quot;now&quot; (current pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrophysiological studies</measure>
    <time_frame>6 weeks</time_frame>
    <description>nerve conduction velocity at the end of the study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Oncology Pain</condition>
  <condition>Chemotherapy-induced Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Venlafaxine Treated Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Memantine Treated Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)</description>
    <arm_group_label>Venlafaxine Treated Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Patients will receive memantine (10 mg) once daily (Morel et al., 2016)</description>
    <arm_group_label>Memantine Treated Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All patients, 18 years of age or older, with a cancer treated with Paclitaxel&#xD;
&#xD;
          2. Patients must have a life expectancy of at least 24 weeks.&#xD;
&#xD;
          3. Patients must sign an informed consent.&#xD;
&#xD;
          4. Patients may have a grade 0 (chemotherapy naive) or 1 neuropathy (history of prior&#xD;
             chemotherapy) prior to entry.&#xD;
&#xD;
          5. Patient matching high risk on the CIPN risk stratification scoring system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with symptomatic brain metastases.&#xD;
&#xD;
          2. Pregnant women or nursing mothers. Patients of child bearing potential must use&#xD;
             adequate contraception.&#xD;
&#xD;
          3. Patients may receive no other concurrent complementary medicines during this study.&#xD;
&#xD;
          4. Patients with neuropathy induced diabetes.&#xD;
&#xD;
          5. Patients with severe medical problems such as uncontrolled diabetes mellitus or&#xD;
             cardiovascular disease or active infections.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gehad Sayed Ahmed, MD</last_name>
    <phone>+201222352664</phone>
    <email>Gehad.S.Fadl@kasralainy.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Cairo University - Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gehad Sayed Ahmed, MD</last_name>
      <phone>+201222352664</phone>
      <email>Gehad.S.Fadl@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 30, 2021</study_first_submitted>
  <study_first_submitted_qc>January 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>January 30, 2021</last_update_submitted>
  <last_update_submitted_qc>January 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>G Fadl</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

